Synalar can be applied to facial skin, but the area should be limited and the frequency reduced (often once daily). Because the facial skin is thinner, prolonged use increases the risk of atrophy and discoloration. Follow your prescriber’s instructions and discontinue if irritation develops.
Typical treatment courses last 2-4 weeks, with reassessment after the first two weeks. If the rash improves, the prescriber may advise tapering the amount or frequency to maintain control while minimizing side-effects.
Fluocinolone acetonide is classified as a Category C medication in many regions, indicating that risk cannot be ruled out. Pregnant patients should discuss potential benefits and risks with their healthcare provider before using Synalar.
Topical fluocinolone acetonide has minimal systemic absorption, so significant interaction with oral antihistamines is unlikely. However, inform your prescriber of all medications you are taking.
Yes. After the steroid has been absorbed (typically a few minutes after application), you can safely apply a broad-spectrum sunscreen to protect treated skin from UV-induced damage.
Stop using Synalar immediately and contact your healthcare provider. Antifungal therapy may be required before re-initiating any corticosteroid treatment.
Coverage depends on the specific public or private insurance plan. Check with your insurer or the Hospital Authority for reimbursement information.
Fluocinolone acetonide (Synalar) is a medium-potency steroid, whereas betamethasone can be medium to high potency depending on formulation. Choice of agent is guided by the severity of the condition, body surface area treated, and patient-specific risk factors.
Yes, provided the cabinet stays at a stable room temperature and does not experience high humidity or direct heat from showers. Avoid storing near the sink where steam may accumulate.
Wipe the tip with a clean tissue or cotton swab and replace the cap securely. This prevents contamination and maintains dosage accuracy for subsequent applications.
Synalar is a topical dermatologic preparation marketed as a tube containing 0.025 % fluocinolone acetonide. Fluocinolone acetonide is a synthetic corticosteroid that belongs to the class of medium-potency topical steroids. In Hong Kong, Synalar is available by prescription only and is regulated by the Hong Kong Department of Health. The tube formulation is designed for easy application to inflamed or pruritic skin areas.
Fluocinolone acetonide exerts its anti-inflammatory effect by binding to intracellular glucocorticoid receptors. Once activated, the receptor complex translocates to the nucleus and modulates gene transcription. This results in:
Because the medication is applied directly to the skin, the systemic absorption is limited, allowing the drug to act locally while minimizing whole-body exposure. The onset of action is typically observed within a few hours, with peak anti-inflammatory effects occurring after several days of consistent use.
Synalar is approved in Hong Kong for the topical treatment of several inflammatory skin disorders, including:
The medication is intended for adult patients and older children who can apply the tube accurately. For pediatric use, a healthcare professional should assess the appropriate potency and duration.
If you fall into any of the categories above, consult your prescriber before initiating therapy.
If any of these occur, stop using Synalar and seek medical advice promptly.
Patients should inform their healthcare provider of all prescribed, over-the-counter, and herbal products they are using.
Because the tube contains a fixed concentration of 0.025 %, dosage statements refer to the amount of product applied rather than milligram strengths.
Regular follow-up with a dermatologist or primary care provider ensures optimal therapeutic outcomes and early detection of adverse effects.
If you need to travel with Synalar, keep the tube in a carry-on bag to avoid temperature extremes in checked luggage.
This article provides educational information about Synalar and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
